Lumibird Medical® is announcing that the HoloDoppler project led by its subsidiary Quantel Medical has been selected as part of the Health section of France 2030, financed by Bpifrance (French public investment bank) to receive €2.8m of public funding, split between Quantel Medical and its partners.
HoloDoppler is moving forward in partnership with the world’s most renowned research and hospital centers for ophthalmology: the Quinze-Vingts National Ophthalmology Hospital, the Adolphe de Rothschild Foundation Hospital and ESPCI Paris.
The HoloDoppler project aims to create a next-generation medical device for quantitative and non-invasive angiography of the eye. It represents a response to an unmet medical need, making it possible to measure ocular blood flow with sufficient temporal and spatial resolution to effectively diagnose and treat pathologies such as glaucoma or hypertension.
The quantitative biomarkers provided in terms of ocular blood flow (speed, flow rate, resistivity) will lead to a companion diagnostic for personalizing patient treatments and follow-up.
The €2.8m grant will cover 60% of the total amount of the project (€4.7m), which aims to take
this technology, which is already operational, to a sufficient level of maturity for it to be
This involves creating databases taking into account several hundred clinical examinations and incorporating artificial intelligence to effectively capitalize on these data. The market for retina imaging devices is currently estimated at €800m per year. The aim is to bring HoloDoppler to the market within four years, targeting a market share in time of around 5%.